AKT1 and prostate cancer: Formononetin has been demonstrated to be highly effective in suppressing the oncogenic PI3K/AKT pathway [122,123,124,125,126,127,128,129,130,131,132] and inducing cell cycle arrest in numerous cell lines, including breast cancer (MCF-7), colorectal cancer (HCT-116 and SW1116) [85], non-small cell lung cancer [96], and prostate cancer (PC-3 and DU-145) [95].